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A B S T R A C T
Background: Surveys of the experience of cancer patients are increasingly being introduced in different
countries and used in cancer epidemiology research. Sampling processes, post-sampling mortality and
survey non-response can influence the representativeness of cancer patient surveys.
Methods: We examined predictors of post-sampling mortality and non-response among patients initially
included in the sampling frame of the English Cancer Patient Experience Survey. We also compared the
respondents’ diagnostic case-mix to other relevant populations of cancer patients, including incident and
prevalent cases.
Results: Of 109,477 initially sampled cancer patients, 6273 (5.7%) died between sampling and survey
mail-out. Older age and diagnosis of brain, lung and pancreatic cancer were associated with higher risk of
post-sampling mortality. The overall response rate was 67% (67,713 respondents), being >70% for the
most affluent patients and those diagnosed with colon or breast cancer and <50% for Asian or Black
patients, those under 35 and those diagnosed with brain cancer. The diagnostic case-mix of respondents
varied substantially from incident or prevalent cancer cases.
Conclusions: Respondents to the English Cancer Patient Experience Survey represent a population of
recently treated cancer survivors. Although patient survey data can provide unique insights for
improving cancer care quality, features of survey populations need to be acknowledged when analysing
and interpreting findings from studies using such data.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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National surveys of the experience of cancer patients are being
introduced in different countries. For example, in England national
surveys of cancer patients have been conducted initially in
2000 and 2004 and subsequently another four times thus far
since 2010, and similar surveys are being planned or have been
recently carried out in countries including the US, Norway,
Germany and Australia [1–4]. The primary objective of such
surveys is to motivate and inform service improvement efforts, but
they also provide new opportunities for research about disparities
in the processes and outcomes of cancer care. A large number of
such research publications has emerged recently, including* Corresponding author at: Health Behaviour Research Centre, Department of
Epidemiology and Public Health, 1-19 Torrington Place, London WC1 E 7HB, UK.
E-mail address: y.lyratzopoulos@ucl.ac.uk (G. Lyratzopoulos).
http://dx.doi.org/10.1016/j.canep.2015.12.010
1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access articresearch examining disparities in patient experience [5–7],
organisational or geographical differences in hospital performance
[8,9] diagnostic timeliness [10–15], or other aspects of cancer
health services improvement research [16–18]. An important
consideration in appropriately interpreting data from such surveys
is the representativeness of respondents which, in the context of
cancer patient surveys, may be limited by three factors.
First, if the surveys focus on care experience (as opposed to
longer term patient-reported outcomes such as the quality of life of
cancer survivors) patients are often sampled following a treatment
episode, typically at a hospital, and they are, therefore, unlikely to
be representative of either incident or prevalent cancer cases.
Second, some of the initially sampled patients will die soon after
their treatment and before they could be asked to participate in a
survey. This poses specific concerns for cancer compared to general
patient surveys, given the relatively high mortality associated with
cancer. Third, response rates may vary between different patient
groups [19]. Altough socio-demographic characteristics (such asle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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any type of survey, in surveys of cancer patients response rates may
be additionally affected by disease severity, with patients with
poor prognosis possibly being too ill to respond.
Direct evidence quantifying how sampling processes, post-
sampling mortality and survey non-response may influence the
representatives of cancer patient surveys is currently lacking, in
spite of the increasing availability and use of such data. Against
this background, we set out to examine the characteristics of
respondents compared to patients included in the sampling frame of
the English Cancer Patient Experience Survey, and compare their
diagnostic case-mix with that of other relevant populations of
cancer patients. In doing so, our aim was to inform how the findings
of research based on cancer patient surveys could be best reported,
interpreted and contextualised by researchers, policy-makers,
clinicians, managers and patient organisations.
2. Methods
2.1. Data
We analysed data from the sampling frame of the 2010 English
Cancer Patient Experience Survey. The survey is carried out by a
specialist survey provider (Quality Health) on behalf of the
Department of Health. The sampling period was 1st of January
to 31st March 2010, and lists of non-deceased patients who
received inpatient or day-case cancer treatment in an NHS hospital
during that period formed the initial sampling frame (Table 1) [20].
Patients eligible for inclusion were identified by each NHS hospital
using the Patient Administration System records. The survey was
mailed out at approximately 2–3 months from the end of the
sampling period (i.e. late May/June 2010). To minimise the risk of
the survey being sent to the former residence of patients who have
died soon after their treatment episode, vital status checks (via
hospital records or through database checks with the Demographic
Batch Service) were conducted during the period from hospital
discharge and survey mail-out, and patients found to have died or
be otherwise ineligible (e.g. due to changed address) were not sent
a survey. Two postal reminders were sent to non-respondents.
Anonymous data on patients initially included in the sampling
frame were made available for research purposes to the authors by
the survey provider.
Information (based on hospital records) on age, sex, ethnicity,
cancer diagnosis, and an ecological measure of socioeconomic
status (2007 Index of Multiple Deprivation (IMD) of the lower
super output area of patients’ residence [21]) was available for
patients in the sampling frame. A 36-group classification of cancer
diagnoses was used, as in previous analyses of data from this
survey, to include patients with both common and rarer cancer
[5,8,9]. Data were complete for all variables other than ethnicity
and deprivation group (which were missing for 8.4% of records in
the sampling frame, Supplementary material 3). For analyses
exploring predictors of either post-sampling mortality or non-
response, only patients with complete covariate information were
included. However, for comparisons with other relevantTable 1
Survey phases and timeline: English Cancer Patient Survey 2010. Please note that other th
varied for individual hospitals.
January–March 2010 April–June 2010 
Patients are treated for cancer at an English
National Health Service (NHS) hospital
Eligible (non-deceased) patients are id
patient lists are sent to the survey pro
Duplicate patients (e.g. treated in more
database and hospital record checks apopulations of cancer patients, all patients (who were either
sampled or responded, as applicable) were included. In line with
best practice, non-eligible patients (including those who had died
before survey mail out, and those who had moved address) were
excluded from the denominator in calculation of response rates
(Supplementary material 3) [20,22].
2.2. Analysis
There were three steps in the analysis. First, using multivari-
able logistic regression (adjusting for age, sex, deprivation,
ethnicity and cancer diagnosis) we examined predictors of
post-sampling mortality. Here, post-sampling mortality refers
to patients who were initially included in the sampling frame and
were later known to have died before survey mail out. Noting that
when hospitals were aware of deaths (for example in inpatients)
the patient was expected to be excluded from the sampling frame.
In these models, death is used as an outcome and age-group, sex,
deprivation, ethnicity and cancer diagnosis are included as
categorical exposure variables. Secondly, we used multivariable
logistic regression to examine predictors of non-response among
patients who were eligible for inclusion in the denominator (e. g.
excluding those known to have died between the creation of the
sampling frame and survey mail-out). This model used survey
response as the outcome, but otherwise was the same as the
above model for mortality. A random effect for hospital of
treatment was also included in the above regression models to
account for potential clustering of various patient groups within
certain hospitals. Thirdly, we compared the diagnostic case-mix
of respondents and incident cases; and additionally, for patients
with 10 common cancers, we compared the diagnostic case-mix
of patients initially included in the sampling frame with that of
survey respondents, patients admitted to hospital with a
principal diagnosis of cancer, and incident and prevalent cancer
cases in the general population, using information from relevant
external data sources [23–26]. We also used the survey question
on radiotherapy use to explore how treatment modality may
affect survey item non-response [27]. All analyses were carried
out using Stata 11.1.
3. Results
3.1. Predictors of post-sampling mortality after inclusion in the survey
sampling frame
There were 109,475 patients initially included in the sampling
frame, of whom 6273 (5.7%) were identified as having died soon
after their initial inclusion in the sampling frame. Although the
overall degree of sample attrition due to post-sampling mortality
was small, there were large relative differences between different
patient groups. In crude analysis, exclusion from the survey due to
post-sampling mortality was greater for men, older patients, and
those from deprived areas (Table 2, Supplementary material 1,
p < 0.0001 for all). Further, post-sampling mortality was greater
than 10% among patients with a diagnosis of pancreatic (19.3%),an for the sampling period (Jan–Mar 2010), timings are approximate and may have
June
2010
2–3 month period from June 2010
entified by hospitals and initial
vider
Survey
mail out
Completed surveys returned to
survey provider
Mail out of up to two reminders
to initial non-respondents
 than one hospital) are identified and
re made for patient deaths
Table 2
Patient characteristics and cancer diagnoses of respondents to the 2010 Cancer Patient Experience Survey (CPES) and associations with post-sampling mortality and response
rates.a
Sampling
frame
Post-sampling
deaths
(N,%)
Respondents Response
rateb
Sampling
frame
Post-sampling
deaths
(N,%)
Respondents Response
rateb
Age Cancer
16–24 1,149 38 3.3 408 37.9 Ductal carcinoma in
situ
955 4 0.4 732 77.8
25–34 2,212 61 2.8 992 47.4 Thyroid 780 8 1.0 458 61.3
35–44 5,983 205 3.4 3,239 57.0 Testicular 567 6 1.1 275 50.4
45–54 13,208 547 4.1 8,091 64.7 Melanoma 1,808 32 1.8 1,146 65.9
55–64 24,245 1,257 5.2 16,066 70.6 Breast 16,937 302 1.8 12,204 73.8
65–74 29,172 1,744 6.0 19,443 71.8 Bladder 10,544 311 2.9 6,591 65.4
75–84 19,468 1,488 7.6 11,570 65.4 Hodgkin’s lymphoma 946 18 1.9 509 55.3
85+ 4,797 482 10.0 2,172 51.7 Ophthalmic and rarer
CNS
194 4 2.1 108 63.2
Endometrial 1,878 55 2.9 1,269 70.3
Gender Ureter and rarer
urological
544 20 3.7 313 60.2
Men 48,497 3,179 6.6 29,067 65.1 Laryngeal 550 20 3.6 319 61.3
Women 51,737 2,643 5.1 32,914 67.9 Prostate 7,343 302 4.1 4,710 68.2
Non-Hodgkin
lymphoma
5,805 225 3.9 3,768 68.6
Ethnicity Rectal 4,923 213 4.3 3,187 68.4
White 94,447 5,472 5.8 59,382 67.6 Anal 355 15 4.2 208 62.3
Mixed 376 21 5.6 188 54.2 Colon 6,874 319 4.6 4,619 71.2
Asian 2,386 145 6.1 1,022 46.2 Multiple myeloma 4,098 189 4.6 2,569 66.5
Black 1,933 124 6.4 857 48.5 Gynaecological NOS 79 4 5.1 51 68.0
Chinese 228 17 7.5 118 56.2 Vulval/vaginal 417 22 5.3 253 65.7
Other 864 43 5.0 414 52.0 Leukaemia 4,144 233 5.6 2,375 61.8
Bone sarcoma 320 15 4.7 156 51.8
Deprivationc Renal 1,422 92 6.5 843 64.6
Most
affluent
20,809 1,079 5.2 13,932 71.3 Oropharyngeal 2,016 132 6.5 1,147 62.0
2 21,655 1,145 5.3 14,093 69.6 Soft tissue sarcoma 873 58 6.6 494 62.6
3 20,803 1,175 5.6 13,197 68.0 Ovarian 2,620 185 7.1 1,627 68.0
4 19,369 1,167 6.0 11,455 63.8 Small-intestine 382 30 7.9 210 60.9
Least
affluent
17,598 1,256 7.1 9,304 58.1 Cervical 729 48 6.6 359 53.4
Hepato-biliary 993 109 11.0 488 56.0
Any other cancer
diagnosis
1,166 119 10.2 599 59.2
Stomach 1,749 199 11.4 936 61.7
Secondary 6,974 803 11.5 3,836 62.8
Oesophageal 2,457 339 13.8 1,280 61.5
Lung 5,873 878 14.9 3,050 61.8
Mesothelioma 565 92 16.3 315 67.3
Pancreatic 1,199 231 19.3 555 58.4
Brain 1,155 190 16.5 422 44.7
a The sample described here are the 100,234 patients with complete hospital record ethnicity, and deprivation information.
b Calculated as the proportion of people in each group who responded to the survey after excluding ineligible patients (those who had died, and other ineligible patients).
c Measured using the index of multiple deprivation, and quantile-defining cut points 8.257, 13.525, 20.741, and 33.511.
36 G.A. Abel et al. / Cancer Epidemiology 41 (2016) 34–41brain (16.5%), mesothelioma (16.3%), lung (14.9%), oesophageal
(13.8%), stomach (11.4%) and hepato-biliary cancer (11.0%). In
contrast, post-sampling mortality was lowest among patients with
a diagnosis of ductal carcinoma in situ (0.4%), thyroid (1.0%),
testicular (1.1%), melanoma (1.8%) and breast cancer (1.8%)
(p < 0.0001 for variation in post-sampling mortality by cancer).
Multivariable logistic regression confirmed very large (>50-fold)
variation by cancer diagnosis in the adjusted odds of post-sampling
mortality after initial inclusion in the sampling frame. Those with
brain cancer, pancreatic cancer and mesothelioma were most likely
to have died between sampling and survey mail-out [adjusted odds
ratio compared with patients with rectal cancer (95% confidence
interval) 5.46 (4.39–6.79), 5.28 (4.31–6.48) and 4.59 (3.51–6.01),
respectively]. In contrast, patients with ductal carcinoma in situ,
thyroid and testicular cancer diagnoses were least likely to have
died between sampling and survey mail-out [adjusted odds ratio
compared with patient with rectal cancer of 0.11 (0.04–0.30) 0.09,0.30 (0.14–0.60) and 0.35 (0.15–0.79), respectively] (Fig. 1,
Supplementary material 1, p < 0.0001 for variation in post-
sampling mortality by cancer).
3.2. Predictors of non-response
After excluding patients who died between sampling and
survey mail-out or were otherwise ineligible, the overall survey
response rate was 67% (Supplementary material 3). Response rates
varied between different patient groups and were greater than 70%
among patients aged from 55 to 74, those living in the most
affluent areas and among patients with colon, endometrial, breast
cancer or ductal carcinoma in situ. In contrast, the response rate
was less than 50% among cancer patients aged under 35, Asian or
Black patients, and those with brain cancer (Table 2, Supplemen-
tary material 1, p < 0.0001 for variation in non-response by age,
sex, ethnicity, deprivation and cancer). Multivariable analysis
Fig.1. Variation in post-sampling mortality: adjusted odds ratios of post-sampling mortality after initial inclusion in the sampling frame, by socio-demographic characteristic
and cancer diagnosis. (p < 0.0001 for age and cancer diagnosis, p = 0.0047 for sex, p = 0.45 for ethnicity, p = 0.0002 for deprivation; estimates from multivariable regression,
adjusted for all variables shown).
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loss of significance in variation by sex (Fig. 2). However, in contrast
with the large variation in odds of short-term mortality by cancer
diagnosis (see above), there was relatively limited (<4-fold)Fig. 2. Variation in non-response: adjusted odds ratios for survey non-response by socio
for sex; estimates from multivariale regession, adjusted for all vaiables shown).variation in odds of non-response between patients with different
cancers. Moreover, in its greatest part variation in non-response
was concentrated in a few cancers, and after excluding ductal
carcinoma in situ, breast and brain cancer there was <2-fold-demographic characteristic and cancer diagnosis. (p < 0.0001 for all except p = 0.90
Fig. 3. Relative frequency of ten common cancer diagnosis groups across different populations of cancer patients. Note that the diagnostic case-mix of CPES respondents is
quite similar to that of cancer-related hospital admissions, but quite dissimilar to that of incident or prevalent cancer cases. (Exact figures and number of patients/cases are
given in Supplementary material 2).
38 G.A. Abel et al. / Cancer Epidemiology 41 (2016) 34–41variation in the odds of non-response between patients with the
other (33) cancer diagnosis groups.
3.3. Comparison of cancer diagnosis case mix of surveyed and other
relevant cancer patient populations
There are overall substantial differences in the diagnostic case-
mix of survey respondents and incident cases (Supplementary
material 4). Specifically, we compared the diagnostic case-mix of
survey respondents with other relevant cancer populations for
patients with 10 common cancers. Firstly, we note that the
diagnostic case-mix of survey respondents (regarding the 10 com-
mon cancers) is very similar to that of the sampling frame (Fig. 3,
comparing column 1 with 2). Second, the diagnostic case-mix of
respondents was broadly similar to that of patients admitted to
hospital with a principal diagnosis of cancer, with few exceptions
such as for leukaemia and multiple myeloma (Fig. 3, comparing
column 1 with 4). Thirdly, the diagnostic case-mix of respondents
(and sampled patients) differs substantially from that of either
incident or prevalent cases in the general population (Fig. 3,
comparing columns 1–2 with 5–6). For example, patients with
bladder cancer are over-represented among survey respondents
and sampled patients, compared with both incident and prevalent
cases. Finally, we note that the diagnostic case-mix of survey
respondents who replied to questions specific to certain treatment
modalities may be very different to that of respondents and
sampled patients, as exemplified by respondents treated by
radiotherapy (Fig. 3, comparing columns 1–2 with 3).
4. Discussion
4.1. Main findings
Respondents to the English Cancer Patient Experience Survey
represent a population of cancer survivors who have recently
received hospital treatment for their cancer. Consequently, the
diagnostic case-mix of respondents varies substantially from both
that of incident and prevalent cases in the general population. After
inclusion in the sampling frame, older and lower socioeconomic
status patients and those with poor prognosis cancers experience
a higher risk of post-sampling mortality during the short
(2–3 month) period from their treatment and survey mail out.Among patients who could provide a response, non-respondents
are more likely to be young, non-White and socioeconomically
deprived, with no difference by sex. Although both post-sampling
mortality and response rate vary by cancer, this variation has
relatively little impact on the diagnostic case-mix of respondents
with 10 common cancers compared to the sampling frame.
4.2. Findings in the context of previous work; what is known and what
this study adds
The observed patterns of variation in post-sampling mortality by
cancer reflect general patterns of variation in survival for different,
good, average and poor prognosis cancers [28]. There were notable
differences in post-sampling mortality (i.e. between sampling frame
creation and survey mail-out) by deprivation group, which seem to
reflect known socioeconomic inequalities in cancer survival [29].
These observations illustrate the potential for differential patterns of
post-sampling mortality to affect the representativeness of cancer
patient surveys, a concern that is particularlyapplicable to surveys of
cancer patients because of the relatively high mortality associated
with cancer. Nonetheless, in the context of the Cancer Patient
Experience Survey there is a relatively short interval between
treatment and mail-out, which minimises the effect of differential
post-sampling mortality on the diagnosis case-mix of the cancers of
included patients. Cancer patient surveys with longer intervals
between sample definition and mail out will be more prone to case-
mix distortion due to post-sampling mortality.
The English Cancer Patient Experience Survey has a relatively
high responseratecomparedto otherpatientexperiencesurveys.For
example the US Hospital Consumer Assessment of Healthcare
Providers and Systems survey, the English General Practice Patient
Survey and the English Adult Inpatient Survey have typical response
rates between 30% and 50% [30–32]. However, in spite of a high
response rate, we identified large variation in response rates
between different patient groups. The findings that younger and
more deprived patients and those from ethnic minorities are less
likely to respond to patient experience surveys are consistent with
previous work, but we observed small only differences in response
rates by sex [19]. Variation in response rates by cancer was relatively
small, compared with variation bycancer inpost-sampling mortality
(indeedage appearsto beamore important independent predictorof
non-response than cancer diagnosis—see Fig. 2 which presents the
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cancer diagnosis). For this reason, and in the context of a high overall
response rate, there were only minor differences in the diagnostic
case-mix of common cancers between respondents and sampled
patients.
The diagnostic case-mix of survey respondents is similar
(although not identical) to that observed among patients with a
hospital admission with a principal diagnosis of cancer, but where
differences are noted, they may reflect variation in the need for
multiple treatment episodes, and their frequency between patients
with different cancers. For example, the relative proportion of
patients with a diagnosis of leukaemia or multiple myeloma is
lower among respondents than among patients with hospital
admission for cancer. Some of these patients will have more than
one chemotherapy treatment session during the sampling period
(therefore they will be over-represented among the population of
patients who are admitted to hospital for cancer) but will only be
sampled once and be sent a single questionnaire. In contrast, the
diagnostic case-mix of survey respondents is dissimilar to that of
either incident or prevalent cancer cases. Again these differences
are likely to reflect variation in treatment patterns for different
cancers. This is exemplified by patients with bladder cancer, many
of whom will have follow-up cystoscopies at regular intervals for a
long period after diagnosis as part of their management, and who
are for this reason over-represented among respondents (and
sampled patients), compared with broader populations of incident
or prevalent cancer cases. The converse pattern is apparent for
patients with prostate cancer: relatively few such patients would
receive hospital-based treatments such as surgery or radiotherapy,
and for this reason they are under-represented among respondents
(and sampled patients) compared with incident and prevalent
cases.
4.3. Strengths and limitations
Our study describes the representativeness of a large national
survey of cancer patients examining post-sampling mortality and
non-response patterns. Unlike most of the evidence on predictors
of non-response, in patient surveys in general, we were able to
examine these phenomena using information on cancer type
(diagnosis group) in addition to socio-demographic variables.
Hospital records are known to contain degrees of inaccuracy (e.g.
regarding the assignment of ethnicity [33], or diagnosis) but such
errors could not possibly account for the full size of the very
substantial variations in either post-sampling mortality or non-
response that we observed.
The ascertainment of post-sampling mortality is restricted to
deaths identified between sampling frame creation and survey
mail-out. If hospitals were aware that treated patients died at the
point of sampling frame creation these patients would have been
excluded. Consequently, the findings will underestimate the
overall short-term mortality after hospital treatment for cancer
and may also under-estimate the size of respective variation by
patient group. However, the diagnostic case-mix of cancer-related
hospital admissions and that of patients included in the initial
sampling frame are very similar for common cancers, suggesting
that the potential for under-ascertainment of overall short-term
(i.e. including inpatient as well as post-sampling) mortality after
cancer treatment is likely to be small.
In focusing on sample characteristics and non-response
patterns we are not suggesting that these are the only methodo-
logical issues worthy of consideration when considering the use of
data from surveys of cancer patients for purpose of descriptive
epidemiology. For example, cognitive validation of survey items is
also important.4.4. Implications
Cancer policy makers and users of findings from cancer patient
experience surveys need to be aware of the characteristics of
respondents. As we have shown, in postal surveys of recently
treated cancer patients, respondents are likely to be representative
of cancer survivors who recently received hospital treatment.
However, this may not be true if the interval between sampling
period and survey mail-out is substantial [34]. Because the make-
up of incident, prevalent, and recently treated cases are necessarily
different, no single sampling strategy can provide a selection of
patients that is representative of each one of these populations of
cancer patients.
The implications discussed below are specific to surveys which
sample cancer patients on the basis of recent treatment such as is
the case, for example, with recent studies in England, Germany and
Norway [2,3,12,13]. Surveys which sample different populations
(for example a survey of incident cases in the USA) will have
parallel issues when ascertaining inferences about different
populations [1]. Although our discussion is focusing on surveys
of cancer patients, similar concerns may also apply in context of
surveys of patients with other conditions where mortality,
treatment modality and sample definitions affect the representa-
tiveness of survey results.
Caution is needed in interpreting data from surveys of cancer
patients when they are used to study the care of incident or
prevalent cases (e.g. when studying outcomes relating to processes
of cancer care up to and including diagnosis, or care management
in the community after hospital treatment, respectively). Crude
estimates of outcome prevalence in survey respondents are bound
to be biased compared to the true value in the relevant population
(e.g. incident or prevalent cases). Partial improvement upon such
biased estimates can be achieved by weighting to account for
compositional differences between survey respondents and the
population of relevance [22]. However, such approaches will not
obviate potential for selection bias within strata of the weighting
variables. For example, selection bias which can be introduced
through differential mortality in otherwise similar respondents (in
terms of age, sex, cancer diagnosis etc.) who nonetheless have
differential prognosis.
When data from patient surveys are used to measure hospital
performance recently treated cancer survivors are indeed the
population of prior interest, and this minimises concerns about
generalisability in this context. However, there may still be
concerns about case-mix distortion due to post-sampling mortali-
ty and non-response. Non-response weighting could be applied to
any estimates of prevalence of patient reported outcomes or
hospital scores, as is standard practice in some other surveys (e.g.
the English General Practice Patient Survey). An alternative
approach, which we recommend, is to use case-mix adjusted
estimates of hospital performance. When making comparisons of
hospital performance such estimates would account for the
variable diagnostic and demographic mix of patients treated by
different hospitals; further, under certain assumptions they will
also account for variation in post-sampling mortality and non-
response between hopsitals [9]. Similarly, when the objective of
the analysis is to estimate associations (as is the case in research
aiming to identify disparities in care experience) case-mix
adjustment obviates concerns about potential non-response bias.
While acknowledging different viewpoints about the use of case-
mix adjustment in patient-reported outcomes and disparities
research, in general we advocate public reporting of both crude and
case-mix adjusted estimates of hospital performance of cancer
patient experience [9,35].
Previous work has identified that younger patients and those
from ethnic minorities report poorer experiences of cancer care
40 G.A. Abel et al. / Cancer Epidemiology 41 (2016) 34–41[5,7,9], as do patients with advanced stage cancer (and conse-
quently poor prognosis) [36]. These are the same patient groups
who are likely to be under-represented in survey respondents—a
‘double whammy’ of both survey under-representation and
inequality in experience. We recommend that existing surveys
can be re-designed (or additional surveys designed anew) so that
patients are invited to participate shortly after (or before)
discharge from hospital care. Doing so should be expected to
increase representation of patient groups with poorer prognosis (a
concern also highlighted by advocacy organisations representing
such patients [37]), and might also help to increase response rates.
Certainly long intervals between treatment and survey should be
avoided.
5. Conclusions
`The case-mix of respondents to surveys of cancer patients is
determined largely by the way that the sample is defined. There
are a number of relevant populations that can be defined and no
survey will represent all of them. As is the case with the English
Cancer Patient Experience Survey, respondents will differ from
incident or prevalent cases in the general population if they are
recruited on the basis of recent hospital treatment. Survey
respondents will also differ from the patients initially included
in the sampling frame of these surveys, because of both
differential risk of post-sampling mortality, and differential
non-response, although high response rates and short intervals
between treatment and survey mail-out limit such concerns.
These issues need to be borne in mind when interpreting and
using data from such surveys. If however the experience of
certain patient groups (e.g. of patients with poor prognosis
cancers) is of prime prior interest, alternative survey designs
need to be considered.
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